A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

Trial Profile

A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs LYC 55716 (Primary)
  • Indications Bladder cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms ARGON
  • Sponsors Lycera
  • Most Recent Events

    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
    • 04 Jan 2018 According to a Lycera media release, interim findings expected by the second half of 2018.
    • 16 Nov 2017 Planned number of patients changed from 90 to 105.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top